Status
Conditions
Treatments
Study type
Funder types
Identifiers
About
This is a prospective biomarker study that aims at demonstrating the impact of liquid biopsy to deliver better treatment for cancer patients with metastatic disease managed in the community setting
Full description
Patients will be selected to present a metastatic cancer (de novo or relapse after primary tumor treatment) eligible for a first line treatment (chemotherapy, immunotherapy, endocrine therapy or targeted therapy).
All tumor subtype could be enrolled in the study; metastatic prostate cancer must be resistant to castration. Triple negative breast cancer and Hormone receptor positive, Her2-negative metastatic breast cancer resistant to endocrine therapy are eligible to the study.
A plasma sample will be collected at baseline and will be tested for a large panel of gene and MSI status using Next Generation Sequencing (NGS) (cf table). Results will be discussed within a Molecular Tumor Board (MTB) with all declared centers.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Participants are eligible to be included in the study only if they meet all of the following criteria:
Exclusion criteria
Participants will be excluded from the study if they meet any of the following criteria:
Primary purpose
Allocation
Interventional model
Masking
10,000 participants in 1 patient group
Loading...
Central trial contact
Antoine Italiano, MD; Benjamin Verret, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal